Article
Medicine, Research & Experimental
Irene E. Van der Horst-Bruinsma, Kurt de Vlam, Jessica A. Walsh, Rebecca Bolce, Theresa Hunter, David Sandoval, Danting Zhu, Vladimir Geneus, Enrique R. Soriano, Marina Magrey
Summary: This study found that female patients with axial spondyloarthritis have a higher disease burden. Following treatment with IXE, male patients showed a higher proportion of responders up to 16 weeks, while female patients had less robust responses in the first 16 weeks but larger improvements from weeks 16 through 52.
ADVANCES IN THERAPY
(2022)
Article
Rheumatology
Uta Kiltz, James Cheng-Chung Wei, Desiree van der Heijde, Filip van den Bosch, Jessica A. Walsh, Annelies Boonen, Lianne S. Gensler, Theresa Hunter, Hilde Carlier, Yan Dong, Xiaoqi Li, Rebecca Bolce, Vibeke Strand, Juergen Braun
Summary: This study showed that IXE significantly improved functioning and health in patients with r-axSpA, as assessed by various measures, and these improvements were sustained through 52 weeks.
JOURNAL OF RHEUMATOLOGY
(2021)
Review
Rheumatology
Bon San Koo, Tae-Hwan Kim
Summary: IL-17 inhibitors, such as ixekizumab, have shown effectiveness in treating nr-axSpA patients, offering an alternative to TNFi with positive results in improving signs and symptoms.
THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE
(2021)
Article
Rheumatology
Atul Deodhar, Philip Mease, Proton Rahman, Victoria Navarro-Compan, Helena Marzo-Ortega, Theresa Hunter, David Sandoval, Andris Kronbergs, Luis Leon, Mingyang Shan, Ann Leung, Kurt De Vlam, Vibeke Strand
Summary: The study demonstrates that treatment with Ixekizumab in non-radiographic axial spondyloarthritis patients can lead to significant improvements as early as week 1, with ASAS40 responders showing greater improvements in all response domains and fatigue and spinal pain at night compared to ASAS20 non-responders.
RHEUMATOLOGY AND THERAPY
(2021)
Article
Rheumatology
Walter P. Maksymowych, Rebecca Bolce, Gaia Gallo, Emily Seem, Vladimir J. Geneus, David M. Sandoval, Mikkel Ostergaard, Kurisu Tada, Xenofon Baraliakos, Atul Deodhar, Lianne S. Gensler
Summary: This study evaluated the efficacy of ixekizumab in the treatment of patients with radiographic axial SpA, regardless of elevated CRP levels or evidence of spinal inflammation on MRI. Ixekizumab demonstrated significant efficacy in improving symptoms in these patients.
Article
Oncology
Yu Xue, Jiankang Hu, Dongzhou Liu, Jingyang Li, Huaxiang Wu, Chunyu Tan, Lie Dai, Lingyun Sun, Zhijun Li, Zhengyu Xiao, Cibo Huang, Yan Yan, Fei Ji, Rong Chen, Hejian Zou
Summary: This phase III study evaluated the efficacy and safety of Ixekizumab in Chinese patients with active r-axSpA. The results showed that Ixekizumab was associated with rapid and significant improvements in signs and symptoms of active r-axSpA at week 16, with sustained efficacy at week 52. The safety profile of Ixekizumab was consistent with previous studies, with infections and injection-site reactions being the most commonly reported events of special interest.
Article
Rheumatology
Atul A. Deodhar, Philip J. Mease, Proton Rahman, Victoria Navarro-Compan, Vibeke Strand, Theresa Hunter, Rebecca Bolce, Luis Leon, Steve Lauzon, Helena Marzo-Ortega
Summary: This analysis evaluated improvements in patients with radiographic axial spondyloarthritis treated with ixekizumab over one year, showing sustained and consistent improvements in patient global disease activity, spinal pain, function, stiffness, fatigue, spinal pain at night, and sleep quality. ASAS40 responders demonstrated greater improvements compared to ASAS20 nonresponders, with function and fatigue showing the highest values.
Article
Immunology
Liudan Tu, Churong Lin, Ya Xie, Xiaohong Wang, Qiujing Wei, Yanli Zhang, Jieruo Gu
Summary: This study found that patients with radiographic axial spondyloarthritis (r-axSpA) showed more active inflammatory and chronic structural damages on MRI compared to non-radiographic axial spondyloarthritis (nr-axSpA) patients, especially in terms of fat metaplasia and ankylosis.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Rheumatology
Desiree van der Heijde, Mikkel Ostergaard, John D. Reveille, Xenofon Baraliakos, Andris Kronbergs, David M. Sandoval, Xiaoqi Li, Hilde Carlier, David H. Adams, Walter P. Maksymowych
Summary: This study evaluates the long-term effect of IXE on radiographic changes in the spine in patients with r-axSpA and identifies potential predictors of progression. The majority of patients had no radiographic progression in the spine through 2 years of treatment.
JOURNAL OF RHEUMATOLOGY
(2022)
Article
Rheumatology
Juergen Braun, Uta Kiltz, Atul Deodhar, Tetsuya Tomita, Maxime Dougados, Rebecca Bolce, David Sandoval, Chen-Yen Lin, Jessica Walsh
Summary: The study aimed to evaluate the efficacy and safety of ixekizumab in patients with radiographic and non-radiographic axial spondyloarthritis for up to 116 weeks. Results showed sustained long-term improvements in both subtypes of axSpA, with similar efficacy for patients receiving the approved every 4 weeks dose. The safety profile of ixekizumab was consistent with previous reports.
Article
Rheumatology
Robert B. M. Landewe, Lianne S. Gensler, Denis Poddubnyy, Proton Rahman, Maja Hojnik, Xiaoqi Li, Soyi Liu Leage, David Adams, Hilde Carlier, Filip Van den Bosch
Summary: The objective of the study was to evaluate the effect of continuing or withdrawing ixekizumab in patients with axial spondyloarthritis who had achieved remission. Results showed that patients who continued treatment with IXE were significantly less likely to experience a flare and had a delayed time-to-flare compared to those who withdrew to placebo.
ANNALS OF THE RHEUMATIC DISEASES
(2021)
Article
Rheumatology
Uta Kiltz, Desiree van der Heijde, Annelies Boonen, Lianne S. Gensler, Theresa Hunter Gibble, Jiaying Guo, Hilde Carlier, Juergen Braun
Summary: This study assessed the test-retest reliability, construct validity, known groups discrimination, and responsiveness of the ASAS HI in patients with r-axSpA. The results demonstrated that the ASAS HI showed reliability, validity, discrimination, and responsiveness in adults with r-axSpA in two clinical trials.
JOURNAL OF RHEUMATOLOGY
(2023)
Article
Rheumatology
Walter P. Maksymowych, Xenofon Baraliakos, Robert G. Lambert, Robert Landewe, David Sandoval, Hilde Carlier, Jeffrey Lisse, Xiaoqi Li, Maja Hojnik, Mikkel Ostergaard
Summary: Ixekizumab treatment in patients with non-radiographic axial spondyloarthritis showed significant reductions in erosions and increases in fat lesions and backfill in the sacroiliac joints, suggesting an early repair process.
LANCET RHEUMATOLOGY
(2022)
Review
Rheumatology
Denis Poddubnyy
Summary: This article discusses several challenges related to the concept, diagnosis, and treatment of non-radiographic axial spondyloarthritis (nr-axSpA) in the historical context and in light of recent data. The disease is part of the spectrum of axial spondyloarthritis and is characterized by the absence of definite structural damage in the sacroiliac joints. The introduction of the concept of nr-axSpA has stimulated activities aimed at improving the early diagnosis and treatment of this disease, but it has also raised controversial topics in the field.
Article
Medicine, General & Internal
Atul Deodhar, Filip Van den Bosch, Denis Poddubnyy, Walter P. Maksymowych, Desiree van der Heijde, Tae-Hwan Kim, Mitsumasa Kishimoto, Ricardo Blanco, Yuanyuan Duan, Yihan Li, Aileen L. Pangan, Peter Wung, In-Ho Song
Summary: Upadacitinib demonstrates significant efficacy and safety in patients with non-radiographic axial spondyloarthritis.
Letter
Rheumatology
Walter P. Maksymowych, Robert G. W. Lambert, Mikkel ostergaard, Xenofon Baraliakos
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Article
Dentistry, Oral Surgery & Medicine
Kevin Sheng-Kai Ma, Eshwar Thota, Jing-Yang Huang, Yu-Feng Huang, James Cheng-Chung Wei
Summary: This study found no significant association between dental restorations and the development of oral lichen planus (OLP). However, root canal therapy and tooth extraction were associated with significantly lower odds of OLP.
Letter
Psychology, Clinical
Hui-Yuan Chen, Renin Chang, James Cheng-Chung Wei
PSYCHOLOGICAL MEDICINE
(2023)
Article
Rheumatology
T. Rusman, M. A. C. van der Weijden, M. T. Nurmohamed, C. J. van Denderen, R. B. M. Landewe, P. M. Bet, C. M. A. van der Bijl, C. J. Van der Laken, I. E. van der Horst-Bruinsma
Summary: The study found that 16 weeks of etanercept treatment did not have an impact on disease activity, the chance of biological treatment, or radiographic progression in patients with suspected non-radiographic axial spondyloarthritis.
SCANDINAVIAN JOURNAL OF RHEUMATOLOGY
(2023)
Article
Rheumatology
Victoria Navarro-Compan, Anne Boel, Annelies Boonen, Philip J. Mease, Maxime Dougados, Uta Kiltz, Robert B. M. Landewe, Xenofon Baraliakos, Wilson Bautista-Molano, Praveena Chiowchanwisawakit, Hanne Dagfinrud, Lara Fallon, Marco Garrido-Cumbrera, Lianne Gensler, Bassel Kamal ElZorkany, Nigil Haroon, Yu Heng Kwan, Pedro M. Machado, Walter Maksymowych, Anna Molto, Natasha de Peyrecave, Denis Poddubnyy, Mikhail Protopopov, Sofia Ramiro, In-Ho Song, Salima van Weely, Desiree van der Heijde
Summary: This study aims to define the instruments for the Assessment of SpondyloArthritis international Society-Outcomes Measures in Rheumatology core domain set for axial spondyloarthritis (axSpA). The study selected core outcome instruments through a systematic literature review and assessment of the instruments' psychometric properties. Additionally, the study endorsed additional instruments to enhance the evaluation of axSpA trials.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Review
Rheumatology
Sytske Anne Bergstra, Alexandre Sepriano, Andreas Kerschbaumer, Desiree van der Heijde, Roberto Caporali, Christopher John Edwards, Patrick Verschueren, Savia de Souza, Janet E. Pope, Tsutomu Takeuchi, Kimme L. Hyrich, Kevin L. Winthrop, Daniel Aletaha, Tanja A. Stamm, Jan W. Schoones, Josef S. Smolen, Robert B. M. Landewe
Summary: This systematic literature review examines the efficacy, duration of use, and safety of glucocorticoids (GCs) in the management of rheumatoid arthritis (RA). The study confirms the effectiveness of GCs in treating RA, with most patients able to stop GCs within 12-24 months. However, the use of GCs also carries well-known safety risks, including osteoporotic fractures, serious infections, diabetes, and mortality.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Editorial Material
Rheumatology
Weijie Wang, Yung-Heng Lee, James Cheng-Chung Wei, Philip Mease
INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES
(2023)
Letter
Rheumatology
Xenofon Baraliakos, Christoph Rischpler, Nils-Martin Bruckmann
ARTHRITIS & RHEUMATOLOGY
(2023)
Letter
Rheumatology
Sofia Ramiro, Elena Nikiphorou, Alexandre Sepriano, Augusta Ortolan, Casper Webers, Xenofon Baraliakos, Robert B. M. Landewe, Desiree van der Heijde
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Article
Rheumatology
Victoria Navarro-Compan, Diego Benavent, Dafne Capelusnik, Desiree van der Heijde, Robert B. M. Landewe, Denis Poddubnyy, Astrid van Tubergen, Xenofon Baraliakos, Filip E. van den Bosch, Floris A. van Gaalen, Lianne Gensler, Clementina Lopez-Medina, Helena Marzo-Ortega, Anna Molto, Rodolfo Perez-Alamino, Martin Rudwaleit, Marleen van de Sande, Raj Sengupta, Ulrich Weber, Sofia Ramiro
Summary: This study developed a consensual definition for 'early axial spondyloarthritis-axSpA' and 'early peripheral spondyloarthritis-pSpA' through a systematic literature review and Delphi survey. The results indicated that early axSpA should be based on symptom duration only, without considering the presence of radiographic damage.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Review
Immunology
Christian Schuetz, Xenofon Baraliakos
Summary: Ankylosing spondylitis is an inflammatory disease affecting musculoskeletal and extra-musculoskeletal sites. The immune system plays a crucial role in its pathogenesis, but the exact mechanism is still unclear. This review summarizes the available experimental and genetic data on immune checkpoint signals in ankylosing spondylitis, focusing on markers such as PD-1 and CTLA-4. The findings suggest an impaired negative immune regulation in this disease, providing potential targets for further research and treatment strategies.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY
(2023)
Review
Immunology
Jin-Xian Huang, Yung-Heng Lee, James Cheng-Chung Wei
Summary: Tumor necrosis factor inhibitors are widely used for axial spondyloarthritis, and current guidelines recommend dose reduction instead of withdrawal. This study reviewed and updated the evidence on dose reduction strategies based on prospective and retrospective studies. The core issues and solutions concerning timing, intensity, maintenance, and monitoring of dose reduction were discussed. Remission/relapse and extra-articular manifestations should be considered in individualized dose reduction plans.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2023)
Article
Rheumatology
Xenofon Baraliakos, Effie Pournara, Laura C. Coates, Victoria Navarro-Compan, Ricardo Blanco, Eamonn O'Brien, Barbara Schulz, Robert Landewe
Summary: The re-read of baseline spinal MRIs from the MAXIMISE trial revealed that bone marrow oedema, spinal process inflammation, and post-inflammatory changes are common in PsA patients and can predict treatment effects. Post-inflammatory changes were associated with better clinical outcomes, while degenerative changes were associated with worse outcomes.
Article
Virology
Kevin Sheng-Kai Ma, Ning-Chien Chin, Ting-Yu Tu, Yao-Cheng Wu, Hei-Tung Yip, James Cheng-Chung Wei, Ren-in Chang
Summary: This cohort study investigated the correlation between HPV infections and the risk of osteoporosis. It found that patients with HPV infections had a significantly higher risk of osteoporosis. Subgroup analysis revealed that females, those aged between 60 and 80 years, and patients with long-term use of glucocorticoids were at greater risk. Furthermore, treatments for HPV infections attenuated the risk of HPV-associated osteoporosis.
Editorial Material
Rheumatology
Po-Cheng Shih, Shu-Hao Chang, An-Ping Huo, James Cheng-Chung Wei
INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES
(2023)